Literature DB >> 29408685

Perspectives on diagnostic strategies for hyperglycemia in pregnancy - Dealing with the barriers and challenges in South Asia.

Anil Kapur1, Hema Divakar2, Veeraswamy Seshiah3.   

Abstract

Estimates indicate that south Asia accounts for over two fifths of the global burden of hyperglycemia in pregnancy (HIP) and the ongoing nutritional and epidemiological transition may make the situation worse. Given their higher risk, all women of south Asian decent require to be tested for HIP. With approximately 37 million births annually in the region requires that 37 million women be tested annually; thereby placing a huge burden on the fragile inadequately resourced health systems in the region with poor awareness and lack of trained manpower. Recommendation for testing must therefore be pragmatic, feasible, convenient and cost effective. Diabetes in pregnancy study group India (DIPSI) has proposed a simple testing protocol that is endorsed by the Indian National Guideline on GDM, and by the FIGO guideline on HIP for use in South Asia. This testing protocol has received widespread support in the region. Despite the many challenges it is encouraging to note that in the four large countries in the region - Bangladesh, India, Pakistan and Sri Lanka which account for over 80% of the estimated burden of HIP in south Asia, large scale credible programs have been initiated to address the identified barriers.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Barriers and challenges; Diagnostic strategies; Hyperglycaemia in pregnancy; South Asia

Mesh:

Year:  2018        PMID: 29408685     DOI: 10.1016/j.diabres.2018.01.025

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  1 in total

1.  Prevalence of gestational diabetes mellitus among women attending antenatal care at public health centers in Rwanda.

Authors:  Pamela M Meharry; Olive Tengera; Stephen Rulisa; Adolphe Karegeya Byambu; Paul J Nietert; Samuel Byiringiro; Callixte Habimana; Crispin Gishoma; Louise R King
Journal:  Diabetes Res Clin Pract       Date:  2019-04-01       Impact factor: 5.602

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.